This is one of the most important questions we get, and we want to address it directly.
In 2002, a large study called the Women’s Health Initiative (WHI) raised concerns about hormone therapy and breast cancer. The resulting panic led millions of women to stop HRT, and many doctors stopped prescribing it altogether. For over 20 years, that fear shaped how women and their doctors approached menopause treatment.
Here’s what has changed since then:
- A 20-year follow-up to the original WHI study found no increase in deaths from breast cancer or heart disease among women who used estrogen-based hormone therapy.
- Current medical consensus holds that for most healthy, symptomatic women under 60, or within 10 years of menopause, the benefits of HRT outweigh the risks.
- In February 2026, the FDA approved labeling changes to menopausal hormone therapy products and removed several boxed-warning statements that had been in place for years, reflecting the updated evidence.
- Modern HRT uses bioidentical formulations and delivery methods (like transdermal estrogen and micronized progesterone) that have a more favorable safety profile than the older formulations used in the original WHI study.
That said, HRT is not right for every woman. Women with a history of hormone-sensitive cancers, blood clots, stroke, or certain other conditions may not be candidates. That’s why every Nuvella patient has a thorough consultation with a licensed clinician before any treatment is prescribed. Your provider will review your individual risk factors, explain the benefits and risks clearly, and help you make an informed decision.
We believe you deserve honest answers, not fear-based headlines. If you have questions about whether HRT is safe for you specifically, your Nuvella provider and nurse care team are here to walk through it with you.
Source: WHI 20-year follow-up data; Menopause Society 2022 Position Statement; FDA Feb. 2026 labeling changes (S5 in source appendix); JAMA Internal Medicine 2025 secondary analysis.